SCHEMBL31199734

SCHEMBL31199734

OC[C@@H]1CN(c2ccc(-c3c(O)cc(Cl)cc3Cl)nn2)CCO1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.45
IL1B P01584 4/20 0.43
NLRP3 Q96P20 4/20 0.43
TNF P01375 1/20 0.43
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
AKT1 P31749 1/20 0.40
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
LRRK2 Q5S007 4/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PPARG P37231 1/20 0.35
NR2E3 Q9Y5X4 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31199386 0.91 PIK3CD (0.41) CNR2IL1BNLRP3TNFPIK3CD
SCHEMBL31199347 0.91 CNR2 (0.44) CNR2IL1BNLRP3TNFAKT1
SCHEMBL31199505 0.91 CNR2 (0.44) CNR2IL1BNLRP3TNFAKT1
SCHEMBL31199588 0.91 AKT1 (0.40) CNR2IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199629 0.91 CNR2 (0.44) CNR2IL1BNLRP3TNFAKT1
SCHEMBL31199372 0.88 CNR2 (0.44) CNR2IL1BNLRP3TNFAKT1
SCHEMBL31199473 0.88 NLRP3 (0.42) CNR2IL1BNLRP3TNFLRRK2
SCHEMBL31199552 0.88 CNR2 (0.44) CNR2IL1BNLRP3TNFAKT1
SCHEMBL31199482 0.88 NLRP3 (0.42) CNR2IL1BNLRP3TNFLRRK2
SCHEMBL31199653 0.87 PIK3CD (0.44) CNR2PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP claimed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US claimed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO claimed
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 CNR2 35/4885IL1B 66/4885NLRP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.